Story

NewAmsterdam Pharma CEO Michael Davidson Acquires $226,500 in Company Stock

ENTHMSVIIDZHZH-TWJAKOHI
Sep 15, 20261 min read
NewAmsterdam Pharma CEO Michael Davidson Acquires $226,500 in Company Stock
Text size
Background

Shares of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS) rose in after-hours trading after the company's chief executive officer made a significant open-market stock purchase. The transaction, disclosed in a regulatory filing, is often interpreted by investors as a strong signal of insider confidence in a company's future prospects.

Details of the Transaction

According to a Form 4 filed with the U.S. Securities and Exchange Commission, CEO and director Michael H. Davidson purchased 10,000 ordinary shares on September 14, 2026. The shares were acquired at a price of $22.65 each, for a total investment of $226,500.

Insider buying, particularly by a C-suite executive like a CEO, is a closely watched event. Such purchases can suggest that the company's leadership believes the stock is undervalued and poised for growth, based on their intimate knowledge of the business.

Updated Executive Holdings

Sample IUX Markets – In-articleAd

Following the purchase, Davidson's direct holdings in NewAmsterdam Pharma increased to 792,923 ordinary shares. This figure includes 163,352 shares from restricted stock unit awards that are still subject to vesting conditions.

The filing also noted that Davidson indirectly holds an additional 285,715 ordinary shares through a grantor retained annuity trust. This multi-faceted holding structure underscores a significant personal financial stake in the company's performance.

Market Reaction

In response to the disclosure, NewAmsterdam Pharma's stock price climbed 4% in after-hours trading. The positive market reaction reflects investor sentiment that often views substantial insider buying as a bullish indicator for the stock's future trajectory.

Read next

More on Stocks
Back to latest news

LATEST